KeyCorp Weighs in on Icon Plc’s Q1 2018 Earnings (ICLR)

Icon Plc (NASDAQ:ICLR) – Stock analysts at KeyCorp lowered their Q1 2018 EPS estimates for shares of Icon in a report issued on Tuesday. KeyCorp analyst D. Hooker now anticipates that the medical research company will post earnings per share of $1.40 for the quarter, down from their previous estimate of $1.42. KeyCorp has a “Buy” rating and a $130.00 price objective on the stock. KeyCorp also issued estimates for Icon’s Q3 2018 earnings at $1.55 EPS, Q4 2018 earnings at $1.61 EPS, FY2018 earnings at $6.02 EPS and FY2019 earnings at $6.98 EPS.

Icon (NASDAQ:ICLR) last posted its quarterly earnings results on Thursday, October 26th. The medical research company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.32 by $0.03. The firm had revenue of $440.30 million for the quarter, compared to analyst estimates of $438.09 million. Icon had a net margin of 16.37% and a return on equity of 28.42%. Icon’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the business posted $1.19 earnings per share.

Other equities analysts have also issued reports about the stock. Jefferies Group boosted their price target on shares of Icon from $122.00 to $132.00 and gave the stock a “buy” rating in a research report on Monday, October 9th. Robert W. Baird restated a “buy” rating and set a $123.00 price target on shares of Icon in a research report on Thursday, October 12th. Zacks Investment Research upgraded shares of Icon from a “hold” rating to a “buy” rating and set a $125.00 price target on the stock in a research report on Monday, September 18th. SunTrust Banks restated a “buy” rating and set a $138.00 price target on shares of Icon in a research report on Sunday, October 29th. Finally, ValuEngine upgraded shares of Icon from a “hold” rating to a “buy” rating in a report on Sunday, December 31st. Three research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $121.82.

Icon (NASDAQ:ICLR) opened at $117.81 on Thursday. The firm has a market cap of $6,370.00, a PE ratio of 22.88, a P/E/G ratio of 1.63 and a beta of 0.61. Icon has a 52-week low of $76.46 and a 52-week high of $124.48. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.90 and a current ratio of 1.90.

Large investors have recently bought and sold shares of the business. Acrospire Investment Management LLC boosted its holdings in Icon by 20.1% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,195 shares of the medical research company’s stock valued at $117,000 after purchasing an additional 200 shares during the last quarter. SG Americas Securities LLC acquired a new position in Icon in the 3rd quarter valued at about $148,000. Sheaff Brock Investment Advisors LLC acquired a new position in Icon in the 2nd quarter valued at about $208,000. Commonwealth Equity Services Inc acquired a new position in Icon in the 3rd quarter valued at about $208,000. Finally, Holderness Investments Co. acquired a new position in Icon in the 3rd quarter valued at about $216,000. Institutional investors own 89.66% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “KeyCorp Weighs in on Icon Plc’s Q1 2018 Earnings (ICLR)” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.com-unik.info/2018/01/11/keycorp-weighs-in-on-icon-plcs-q1-2018-earnings-iclr.html.

Icon Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Earnings History and Estimates for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit